Evidence map›Paper›PMID 38416975›Full record

ArticleJournal of breast imaging2022

Women's Experience With Screening Mammography During the COVID-19 Pandemic: A Multi-Institutional Prospective Survey Study.

Molly B Carnahan, Richard E Sharpe, Eniola Oluyemi, Laura Parra, Daniel S Hippe, Roxanne Lorans, Hannah Perry, Tammy Hui Lin Moey, Neeti Bagadiya, Janie M Lee

Abstract read
In one paragraph

Article in Journal of breast imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Molly B CarnahanMayo Clinic Arizona, Department of Radiology, Phoenix, AZ, USA.ORCID 0000-0001-9323-150X
Richard E SharpeMayo Clinic Arizona, Department of Radiology, Phoenix, AZ, USA.
Eniola OluyemiJohns Hopkins School of Medicine, Department of Radiology, Baltimore, MD, USA.
Laura ParraMayo Clinic Arizona, Department of Radiology, Phoenix, AZ, USA.
Daniel S HippeFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.ORCID 0000-0003-2427-4404
Roxanne LoransMayo Clinic Arizona, Department of Radiology, Phoenix, AZ, USA.
Hannah PerryUniversity of Vermont, Department of Radiology, Burlington, VT, USA.
Tammy Hui Lin MoeySingapore General Hospital, Department of Diagnostic Radiology, Singapore, Singapore.ORCID 0000-0003-3871-9988
Neeti BagadiyaEmory University, Department of Radiology, Atlanta, GAUSA.
Janie M LeeUniversity of Washington, Department of Radiology, Seattle, WA, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

objectiveEvaluate women's anxiety and experience undergoing screening mammography during the COVID-19 pandemic.

methodsAn IRB-approved anonymous survey was administered to women receiving screening mammography across six sites in the U.S. and Singapore from October 7, 2020, to March 11, 2021. Using a 1-5 Likert scale, women rated their pre- and post-visit anxiety regarding having their mammogram during the COVID-19 pandemic, importance of observed COVID-19 precautions, and personal risk factors for breast cancer and severe COVID-19 illness. Post-visit change in anxiety was evaluated. Multivariable logistic regression was used to test associations of pre-visit anxiety with breast cancer and COVID-19 risk factors.

resultsIn total, 1086 women completed the survey. Of these, 59% (630/1061) had >1 breast cancer risk factor; 27% (282/1060) had >1 COVID-19 risk factors. Forty-two percent (445/1065) experienced pre-visit anxiety. Pre-visit anxiety was independently associated with risk factors for severe COVID-19 (OR for >2 vs 0 risk factors: 2.04, 95% confidence interval [CI]: 1.11-3.76) and breast cancer (OR for >2 vs 0 risk factors: 1.71, 95% CI: 1.17-2.50), after adjusting for age and site. Twenty-six percent (272/1065) of women reported post-visit anxiety, an absolute 16% decrease from pre-visit anxiety (95% CI: 14%-19%, P < 0.001). Provider masking (941/1075, 88%) and physical distancing (861/1085, 79%) were rated as the most important precautions.

conclusionPre-visit anxiety was associated with COVID-19 or breast cancer risk factors and declined significantly after screening mammography. Provider masking and physical distancing were rated the most important precautions implemented by imaging clinics.

Indexed as

breast cancerCOVID-19screening mammography

Identifiers

PMID38416975
PMCPMC9129165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.